Metastatic Pancreatic Adenocarcinoma MedDRA version: 21.0 Level: LLT Classification code 10033599 Term: Pancreatic adenocarcinoma metastatic System Organ Class: 100000004864
Conditions
Interventions
Product Name: durvalumab
Product Code: MEDI4736
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: DURVALUMAB
CAS Number: 1428935-60-7
Current Sponsor code: MEDI4736
Conce
Sponsors
GERCOR
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Signed and dated informed consent, 2.Age =18 years 3.Body weight >30 kg, 4.Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up, 5.Life expectancy of at least 4 months, 6.Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1, 7.Pathologically confirmed pancreatic adenocarcinoma with distant metastases (stage IV disease), 8.No prior therapy for metastatic disease other than mFOLFIRINOX (in case of previous adjuvant therapy, the interval between the end of adjuvant chemotherapy and relapse must be >6 months), 9.Stability or tumor response (Response evaluation criteria in solid tumors [RECIST] 1.1) after 4 months of mFOLFIRINOX (8 cycles) for metastatic disease, 10.Have tissue from archival tissue sample from surgery or biopsy identified and confirmed as available for study 11.Availability of tumor somatic genetic analyses data, performed during the first 4 months of mFOLFIRINOX (specific informed consent), 12.In case of germinal BRCA gene mutation identified before inclusion the patient can be included until olaparib receives a marketing authorization for the treatment indication of the patients in the study and the treatment is available in the retail pharmacy; it will be prescribed according to the summary product characteristics (SmPC), 13. At least one measurable or evaluable lesion as assessed by CT-scan or MRI according to RECIST 1.1 and feasibility of repeated radiological assessments, 14.Normal organ and bone marrow function prior to administration of study treatment as defined below: - Hemoglobin = 10.0 g/dL with no blood transfusion in the past 28 days, -Absolute neutrophil count (ANC) = 1.5 x 109/L, - Platelet count = 100 x 109/L, - Total bilirubin = 1.5 x institutional upper limit of normal (ULN), -Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 2.5 x institutional ULN unless liver metastases are present in which case = 5x ULN, - Creatinine clearance (CrCl) = 50 mL/min estimated using the Cockcroft-Gault equation, Estimated CrCl =(140-age [years]) x weight (kg) (x F)a serum creatinine (mg/dL) x 72 a F=0.85 for females and F=1 for males. 15.Absence of known dihydropyrimidine dehydrogenase (DPD) deficiency, 16.Female patients must be surgically sterile, or be post-menopausal, or have negative serum pregnancy test if pre-menopausal at inclusion and must commit to using reliable and appropriate methods of contraception during the study and during at least 6 months after the end of study treatment (when applicable). Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply: - Women 1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or
Exclusion criteria
Exclusion criteria: 1.Histology other than PDAC 2.Toxicities after mFOLFIRINOX treatment not resolved to = grade 1 prior to maintenance treatment, except for oxaliplatin induced neuropathy, alopecia, or grade = 2 are permitted 3.Patients with known brain metastases at inclusion, 4.Enrollment in another therapeutic trial 5.Evidence of interstitial lung disease, any active non-infectious pneumonitis, or known active infection including active tuberculosis 6.Hepatitis B virus (HBV; known positive HBV surface antigen (HbsAg) result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV ½ antibodies). 7.Active uncontrolled infection, current unstable, or uncompensated respiratory or cardiac conditions, or active digestive hemorrhages less than 3 months, 8.Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study, 9.Live vaccine administration within 30 days prior to the first dose of study treatment, 10.Treatment with any other investigational medicinal product within 28 days prior to study entry, 11.Other malignancy unless curatively treated with no evidence of disease for = 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), and stage 1, grade 1 endometrial carcinoma, 12.Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, acute coronary syndrome within 6 months prior to starting treatment, prior or current cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent, 13.Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the Investigator or patients with congenital long QT syndrome. Mean corrected QT interval (QTc) for heart rate using the QTcF formula = must be <470 ms, 14.Pregnancy/lactation, 15.Uncontrolled massive pleural effusion or massive ascites, 16.Tutelage or guardianship. Arm A: Specific exclusion criteria for patients with the BRCAness profile in order to receive olaparib 1.Myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/ DS)/acute myeloid leukemia (AML), 2.Unable to swallow orally administered medication and gastrointestinal disorders likely to interfere with absorption of the study medication, 3.Any previous treatment with PARP inhibitor, including olaparib, 4.Concomitant use of known strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors. The required washout period prior to starting olaparib is 2 weeks, 5. Concomitant use of known strong or moderate CYP3A inducers. 6.Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. 7.Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT), 8.Whole blood transfusio
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the efficacy of a molecular-driven maintenance therapy in PDAC patients with disease controlled after 4 months of mFOLFIRINOX chemotherapy in terms of: - PFS at 4 months from inclusion of maintenance therapy with olaparib in patients with the BRCAness profile - PFS from randomization of maintenance therapy with durvalumab plus selumetinib in patients with no BRCAness profile and KRAS-mutated tumors compared to FOLFIRI ;Secondary Objective: All arms: - To assess disease control rate (DCR), - To assess objective response rate (ORR), - To assess overall survival (OS), - To evaluate the tolerance and safety of maintenance therapy strategies, - To assess the impact of treatment on health-related quality of life (HRQoL), - To identify the potential prognostic value of changes in tumor circulating tumor DNA (ctDNA) biomarkers, - To assess potential correlations between tissue and ctDNA alterations. Arm A only: - To identify the potential prognostic value of BRCA mutations at baseline and tumor progression. Arm B only, experimental arm: - To evaluate expression of CD33+ and of markers for mature myeloid or lymphoid cells, - To evaluate whether PD-1, PD-L1, PD-L2, CD3+ and CD8+ T cells, and forehead box P3 expression could be predictive of patients’ response to the study treatment, - To evaluate whether sarcopenia is associated with immune-related adverse events (imAEs) during treatment with durvalumab and selumetinib. ;Primary end point(s): For analysis of the Arm A patients treated with olaparib: The primary endpoint is PFS rate at 4 months from inclusion; For the comparative analysis of the randomized Arms B patients receiving durvalumab plus selumetinib vs Arm C patients receiving FOLFIRI: The primary endpoint is PFS defined as time from randomization to the date of first documented PD. ;Timepoint(s) of evaluation of this end point: Arm A : 4 months Arm B/C : PFS defined as time from randomization to the date of first documented PD | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): -Disease control rate DCR, -Overall response rate ORR, -Overall survival OS, -Toxicities according to CTCAE 5.0, -Quality of Life HRQoL, -The prognostic value of ctDNA biomarkers, -The prognostic value of BRCA mutations at baseline and tumor progression, -The correlations between tissue and ctDNA alterations ;Timepoint(s) of evaluation of this end point: - DCR is the percentage of patients who achieve CR, PR, or SD to study treatment (according to RECIST 1.1). - ORR is the number of patients with a best overall response of CR or PR divided by the number of all treated (at least 1 dose of study treatment) patients. - OS is the time between the date of inclusion into Arm A or Arms B/C and death. - Toxicity will grade the severity of AEs according to CTCAE version 5.0. - HRQoL :EORTC QLQ-C30 and QLQ-PAN 26 at baseline, at every 2 months during treatment, and at the end of treatment visit. - Blood samples : at baseline, every 2 months up to 24 months from inclusion, and at treatment discontinuation. - Tumor collection : biopsies (mandatory) initial diagnostic and optional re-biopsies obtained before starting treatment | — |
Countries
France
Contacts
Public ContactRegulatory Affairs
GERCOR
Outcome results
None listed